rAAV U7snRNA Exon 2 Skipping for DMD Duplication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Duchenne Muscular Dystrophy (DMD) caused by duplication of DMD exon 2 are limited, with existing exon-skipping therapies showing a plateau in walking ability after initial improvements, and there is a need for effective treatments that address this specific mutation type.

Innovation Solution

The use of recombinant adeno-associated virus (rAAV) vectors carrying a U7 small nuclear RNA (snRNA) polynucleotide construct targeting exon 2, which is delivered to patients to inhibit dystrophic pathology and improve muscle function by skipping the duplicated exon, thereby restoring dystrophin expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If exon-skipping therapies are used to treat DMD caused by exon 2 duplication, then initial walking ability improves, but walking ability plateaus after initial improvement

Engineering Contradiction:

Improvewalking abilityVSAvoidduration of walking improvement

Core Design Contradiction:

SpeedVSDuration of action of moving object

Solution Approach 1:

The patent changes the molecular mechanism parameter from conventional exon-skipping approaches to U7snRNA-mediated splice modulation. This parameter change enables sustained dystrophin production by targeting the splicing process at the pre-mRNA level, thereby maintaining walking ability improvements over longer durations without plateauing.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the mechanical/chemical approach of conventional exon-skipping therapies with a biological system using U7snRNA and spliceosome machinery. This substitution allows for more precise and sustained control of splice site selection, leading to prolonged therapeutic effect on walking ability.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If conventional exon-skipping therapies are used for DMD treatment, then some functional improvement is achieved, but treatment is ineffective for duplication mutations

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidapplicability to different mutation types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates a universal therapeutic platform using U7snRNA that can treat both deletion and duplication mutations of the DMD gene. By targeting splice sites rather than relying on mutation-specific mechanisms, the therapy achieves broad applicability across different mutation types while maintaining high reliability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent inverts the conventional approach by instead of trying to make the therapy adapt to each mutation type, it uses a mechanism (U7snRNA splice modulation) that works regardless of mutation type. This inversion of the problem-solving approach achieves both reliability and versatility simultaneously.

Inventive Principle:

Principle #13The other way round (Inversion)

3Productivity

If rAAV vectors are used to deliver U7snRNA constructs, then high cell transduction efficiency is achieved, but delivery system complexity increases

Engineering Contradiction:

Improvecell transduction efficiencyVSAvoiddelivery system complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent uses rAAV vectors as intermediary carriers to deliver the U7snRNA constructs into muscle cells with high efficiency. The rAAV vector serves as a mediator that simplifies the delivery process despite its inherent complexity, achieving superior transduction compared to direct injection or viral transduction methods.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20230025574A1Recombinant Adeno-Associated Virus Delivery of Exon 2-Targeted U7SNRNA Polynucleotide Constructs

Publication Date: 2023.01.26 RES INST AT NATIONWIDE CHILDRENS HOSPITAL

AI summary

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.